Accessibility Menu
Hemogenyx Pharmaceuticals Plc logo

Hemogenyx Pharmaceuticals Plc(LSE) HEMO

Market Cap£43.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-47%
5 Year-15%
1 Year+304%
1 Month-16%
£6.16
-3.75%
-0.24Today
Hemogenyx Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeGBX 632.502026-07-30
Hemogenyx Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.43%GBX 676.002026-07-23
1 month-16.11%GBX 754.002026-06-30
3 month-6.5%GBX 676.502026-05-01
Year to date+10.58%GBX 572.002025-12-31
1 year+303.51%GBX 156.752025-07-30
3 year+5.42%GBX 600.002023-07-31
5 year-14.53%GBX 740.002021-07-30
Since inception-47.29%GBX 12.002017-10-06

Hemogenyx Pharmaceuticals Plc Financials at a Glance

Market Cap

£43.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£12.57M

EPS (TTM)

-£2.20

P/E Ratio

-2.87

Dividend

£0.00

Beta (Volatility)

0.06 (Low)

Price

£6.16

Volume

11,943

Open

£6.55

Previous Close

£6.16

Daily Range

£6.15 - £6.55

52-Week Range

£1.30 - £18.00

Estimated Earnings Date

Apr 27, 2026

HEMO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company focused on developing innovative therapies for blood diseases. The company aims to advance treatments in the bone marrow and hematopoietic stem cell transplant sector, targeting conditions like acute myeloid leukaemia.

Products and Services
  • CDX bi-specific antibody for relapsed/refractory acute myeloid leukaemia
  • HEMO-CAR-T therapy utilizing chimeric antigen receptor T-cells
  • Human Postnatal Hematopoietic Endothelial Cells for transplant procedures
Growth Outlook
  • Strong focus on innovative therapies positions the company for future growth
  • Pipeline includes treatments for high unmet medical needs in oncology
  • Potential partnerships could enhance development and commercialization efforts
Financial Highlights
  • Recent quarterly net income of -£4.76 million reflects ongoing investment in R&D
  • Cash and cash equivalents of £1.59 million as of Q4 2025
  • Trailing twelve months (TTM) P/E ratio of -3.65 indicates significant growth potential
Hemogenyx Pharmaceuticals is dedicated to addressing critical challenges in blood disease treatment. The company's innovative pipeline, including therapies that could replace traditional chemotherapy, highlights its commitment to advancing medical science. Despite recent financial losses, the focus on research and development suggests a long-term strategy aimed at capturing market opportunities in the biotechnology sector. The potential for partnerships and collaborations may further enhance the company's growth trajectory, making it an intriguing prospect for investors interested in the biotechnology field.
AI Generated • Jul 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Vladislav Sandler, PhD

Website

hemogenyx.com

Headquarters

London, GL W1B 4BT, GB

HEMO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-2807.75%

Return on Capital

-145.67%

Return on Assets

-233.73%

Earnings Yield

-34.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£43.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.80M

Volume

11.94K

Avg. Volume

15.32K

Financials (TTM)

Gross Profit

-£1.55M

Operating Income

-£7.35M

EBITDA

-£13.45M

Operating Cash Flow

-£5.23M

Capital Expenditure

-£17.21K

Free Cash Flow

-£5.25M

Cash & ST Invst.

£1.59M

Total Debt

£2.00M

Hemogenyx Pharmaceuticals Plc Performance Analysis

Hemogenyx Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
Hemogenyx Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Hemogenyx Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -2.06-22.0%
20232023-12-31GBP -2.3715.4%
20242024-12-31GBP -1.70-28.2%
20252025-12-31GBP -2.2029.1%
Hemogenyx Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3099.9%
Q42024-12-31-88788.9%
Q22025-06-30-77.5%
Q42025-12-3144.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£274.97K

+15.6%

Gross Margin

0.00%

N/A

Market Cap

£43.01MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.69M

N/A

Employees

16

N/A

Net Income

-£4.76M

-100.7%

EBITDA

-£1.81M

+4.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.59M

+27.2%

Total Debt

£2.00M

-32.0%

Accounts Receivable

£8.78K

+70.8%

Inventory

£0.00

N/A

Long Term Debt

£1.56M

-41.6%

Short Term Debt

£442.42K

-19.0%

Return on Assets

-2.34%

N/A

Return on Invested Capital

-1.72%

N/A

Free Cash Flow

£336.34K

+111.7%

Operating Cash Flow

£336.34K

+112.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
POLB.LPoolbeg Pharma PLC
£0.06+1.59%
HVO.LhVIVO plc
£0.08+6.90%
KOO.LKooth plc
£1.52+0.00%
SBTX.LSkinBioTherapeutics Plc
£0.12-2.08%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About HEMO

What is the current price of Hemogenyx Pharmaceuticals Plc?

Hemogenyx Pharmaceuticals Plc is trading at £6.16 per share.

What is the 52-week range for Hemogenyx Pharmaceuticals Plc?

Over the past 52 weeks, Hemogenyx Pharmaceuticals Plc has traded between £1.30 and £18.00.

How much debt does Hemogenyx Pharmaceuticals Plc have?

As of the most recent reporting period, Hemogenyx Pharmaceuticals Plc reported total debt of £2.00M.

How much cash does Hemogenyx Pharmaceuticals Plc have on hand?

Hemogenyx Pharmaceuticals Plc reported £1.59M in cash and cash equivalents in its most recent financial results.

What is Hemogenyx Pharmaceuticals Plc’s dividend yield?

Hemogenyx Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services